Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.45 USD | -3.40% | -1.02% | -17.04% |
May. 03 | UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating | MT |
May. 02 | InMode Shares Rise; Q1 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Cut | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.04% | 1.56B | - | ||
+10.22% | 223B | B | ||
+12.99% | 194B | B- | ||
+18.09% | 141B | B- | ||
+28.66% | 109B | A- | ||
+1.48% | 64.85B | A- | ||
+14.70% | 52.7B | B+ | ||
+6.68% | 51.77B | B+ | ||
+8.29% | 44.12B | A | ||
+2.60% | 36.21B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- INMD Stock
- Ratings InMode Ltd.